Clinical Trials

Several clinical trials evaluate diagnostic dye applications involving carmine and related chromoendoscopy agents for gastrointestinal and pediatric indications, such as Lynch syndrome, inflammatory bowel diseases, colonic polyps, ulcerative colitis, and very low birth weight preterms. Encompassing Phase 1, combined Phase 2/Phase 3, and non-applicable interventional designs, these studies are primarily sponsored by academic and clinical institutions, including the Mayo Clinic and Assistance Publique - Hôpitaux de Paris. Reported recruitment statuses across these records include completed, terminated, and unknown trials.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02570516 Completed
Lynch Syndrome
Assistance Publique - Hôpitaux de Paris|ARC Foundation for Cancer Research
2015-11 Not Applicable
NCT01914445 Unknown status
Inflammatory Bowel Diseases
Hillel Yaffe Medical Center
2013-08 Not Applicable
NCT01901510 Completed
Colonic Polyps
Mayo Clinic
2013-05 Phase 1
NCT01536483 Terminated
Very Low Birth Weight Preterms
Nantes University Hospital
2012-02 Phase 2|Phase 3
NCT00961948 Completed
Ulcerative Colitis
Mayo Clinic
2009-06 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Carmine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Carmine selectively binds mucosal surfaces and cellular matrices via physical adsorption, altering local tissue light absorption and enhancing visual topographic contrast without requiring enzymatic activation. This localized staining highlights subtle architectural mucosal dysplasias and vascular irregularities, providing key diagnostic utility for endoscopic identification in conditions such as colonic polyps, ulcerative colitis, and Lynch syndrome.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.